Geoff MacKay
Chairman presso SATELLOS BIOSCIENCE INC.
Patrimonio netto: 1 M $ in data 31/03/2024
Profilo
Geoff MacKay was the founder of Avrobio, Inc. (founded in 2015) where he held the title of President, Chief Executive Officer & Director until 2023.
He is also the founder of eGenesis, Inc. (founded in 2015) where he held the title of Chief Executive Officer & Director until 2017.
Currently, Mr. MacKay is the Chairman of Satellos Bioscience, Inc. (since 2018) and a Director at RedactBio, Inc. (current position).
In the past, he served as the President & Chief Executive Officer of Organogenesis, Inc. from 2003 to 2014.
Mr. MacKay has also held positions as Chairman of the Massachusetts Biotechnology Council and the Alliance for Regenerative Medicine.
He has served as an Independent Director at RepliCel Life Sciences, Inc., a Director at the Centre For Commercialization of Regenerative Medicine, an Independent Director at Talaris Therapeutics, Inc., and a Director at Gemstone Biotherapeutics LLC.
Additionally, he held the position of Vice President at Novartis AG.
Mr. MacKay has an undergraduate degree from McGill University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
AVROBIO INC
1.74% | 10/04/2023 | 778 343 ( 1.74% ) | 996 279 $ | 31/03/2024 |
SATELLOS BIOSCIENCE INC
0.23% | 07/02/2024 | 254 422 ( 0.23% ) | 95 154 $ | 31/03/2024 |
-.--% | 13/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di Geoff MacKay
| Società | Posizione | Inizio |
|---|---|---|
| SATELLOS BIOSCIENCE INC. | Chairman | - |
RedactBio, Inc.
 RedactBio, Inc. BiotechnologyHealth Technology Redactbio, Inc. engages in gene editing and tissue engineering. The company is headquartered in Lexington, MA. | Director/Board Member | - |
Precedenti posizioni note di Geoff MacKay
| Società | Posizione | Fine |
|---|---|---|
| AVROBIO, INC. | Founder | 01/05/2023 |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Consultant / Advisor | 01/04/2023 |
eGenesis, Inc.
 eGenesis, Inc. Miscellaneous Commercial ServicesCommercial Services eGenesis, Inc. operates research platform to deliver human transplantable cells, tissues, and organs grown in pigs. It uses gene editing technology such as CRISPR to directly address the key virology and immunology hurdles that have impeded xenotransplantation. The company was founded by George M. Church, Yang Luhan, Prashant Mali, Geoff Mackay and Guell Marc in 2015 and is headquartered in Cambridge, MA. | Founder | 01/06/2017 |
Organogenesis, Inc.
 Organogenesis, Inc. Medical SpecialtiesHealth Technology Organogenesis, Inc. designs and manufactures regenerative medical products. It offers Apligraf, a living cell-based product indicated for the treatment of venous leg ulcers and diabetic foot ulcers and Dermagraft, a product for the treatment of diabetic foot ulcers. The firm also provides bioactive wound healing, biosurgery, and aesthetic medicine containing living cells and natural connective tissues. The company was founded in 1985 and is headquartered in Canton, MA. | Chief Executive Officer | 01/12/2014 |
Satellos Bioscience, Inc. /Old/
 Satellos Bioscience, Inc. /Old/ BiotechnologyHealth Technology Satellos Bioscience, Inc. is a regenerative medicine company. The firm is dedicated to developing novel therapeutics that stimulates or restore muscle regeneration in severe disorders. The company focuses on the discovery that dysregulated muscle stem-cell polarity a process that balances replenishment of muscle stem cells and production of specialized tissue cells can lead to the inability of the body to properly repair and regenerate muscle throughout life. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which the firm has identified as a root cause of the progressive nature of this disease. Satellos believes defects in muscle regeneration play a critical underlying role in numerous muscle disorders spanning rare diseases through to mass market indications. It applies its proprietary MyoReGenXTM discovery platform to identify regulatory pathways and drug candidates to treat muscle disorders where stem cell polarity is dysregulated. Satellos also maintains the rights to two clinical stage legacy assets as a result of the reverse takeover of iCo Therapeutics Inc.: iCo-008 for potential use in eotaxin-1 mediated indications and an oral Amphotericin B delivery system. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada. | Chairman | - |
Formazione di Geoff MacKay
| McGill University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| NOVARTIS AG | Health Technology |
| REPLICEL LIFE SCIENCES INC. | Health Technology |
| AVROBIO, INC. | Health Technology |
| Aziende private | 11 |
|---|---|
Organogenesis, Inc.
Organogenesis, Inc. Medical SpecialtiesHealth Technology Organogenesis, Inc. designs and manufactures regenerative medical products. It offers Apligraf, a living cell-based product indicated for the treatment of venous leg ulcers and diabetic foot ulcers and Dermagraft, a product for the treatment of diabetic foot ulcers. The firm also provides bioactive wound healing, biosurgery, and aesthetic medicine containing living cells and natural connective tissues. The company was founded in 1985 and is headquartered in Canton, MA. | Health Technology |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Massachusetts Biotechnology Council
 Massachusetts Biotechnology Council Miscellaneous Commercial ServicesCommercial Services Massachusetts Biotechnology Council is a premier life sciences and healthcare hub with over 1,600 members dedicated to preventing, treating, and curing diseases through transformative science and technology. The non-profit company is based in Cambridge, MA. MassBio works to advance policy and promote education while providing member programs, events, industry information, and services. The company's mission is to advance Massachusetts' leadership in the life sciences to grow the industry, add value to the healthcare system, and improve patient lives. Founded in 1985 by James P. Sherblom, the CEO is Kendalle Burlin O'Connell. | Commercial Services |
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Health Services |
Centre For Commercialization of Regenerative Medicine
 Centre For Commercialization of Regenerative Medicine BiotechnologyHealth Technology Centre For Commercialization of Regenerative Medicine supports our partners to develop and commercialize cell and gene therapies and regenerative medicine technologies. Its services include business, technical and facilities. The company is headquartered in Toronto, Canada. | Health Technology |
Talaris Therapeutics, Inc.
 Talaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company, which engages in the development of allogeneic hematopoietic stem cell transplantation. The company was founded by Suzanne Ildstad on February 15, 2002 and is headquartered in Wellesley, MA. | Health Technology |
Gemstone Biotherapeutics LLC
 Gemstone Biotherapeutics LLC BiotechnologyHealth Technology Gemstone Biotherapeutics LLC develops therapeutics and devices for wound care. It develops a range of tissue engineering inventions with particular emphasis on vascularization and angiogenesis for health care research and clinical markets. The company was founded in October 2013 and is headquartered in Baltimore, MD. | Health Technology |
eGenesis, Inc.
eGenesis, Inc. Miscellaneous Commercial ServicesCommercial Services eGenesis, Inc. operates research platform to deliver human transplantable cells, tissues, and organs grown in pigs. It uses gene editing technology such as CRISPR to directly address the key virology and immunology hurdles that have impeded xenotransplantation. The company was founded by George M. Church, Yang Luhan, Prashant Mali, Geoff Mackay and Guell Marc in 2015 and is headquartered in Cambridge, MA. | Commercial Services |
Satellos Bioscience, Inc. /Old/
Satellos Bioscience, Inc. /Old/ BiotechnologyHealth Technology Satellos Bioscience, Inc. is a regenerative medicine company. The firm is dedicated to developing novel therapeutics that stimulates or restore muscle regeneration in severe disorders. The company focuses on the discovery that dysregulated muscle stem-cell polarity a process that balances replenishment of muscle stem cells and production of specialized tissue cells can lead to the inability of the body to properly repair and regenerate muscle throughout life. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which the firm has identified as a root cause of the progressive nature of this disease. Satellos believes defects in muscle regeneration play a critical underlying role in numerous muscle disorders spanning rare diseases through to mass market indications. It applies its proprietary MyoReGenXTM discovery platform to identify regulatory pathways and drug candidates to treat muscle disorders where stem cell polarity is dysregulated. Satellos also maintains the rights to two clinical stage legacy assets as a result of the reverse takeover of iCo Therapeutics Inc.: iCo-008 for potential use in eotaxin-1 mediated indications and an oral Amphotericin B delivery system. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada. | Health Technology |
RedactBio, Inc.
RedactBio, Inc. BiotechnologyHealth Technology Redactbio, Inc. engages in gene editing and tissue engineering. The company is headquartered in Lexington, MA. | Health Technology |
| Satellos Bioscience, Inc. |
- Borsa valori
- Insiders
- Geoff MacKay
